ANALYSIS OF CLINICAL PROGNOSTIC FACTORS OF PD-1 IMMUNE CHECKPOINT INHIBITOR TREATMENT IN MALIGNANT MELANOMA AND CUTANEOUS SQUAMOUS CELL CARCINOMA
Kuzmanovszki Daniella
Clinical Medicine
Dr. Reusz György
SE Bőr-, Nemikórtani és Bőronkológiai Klinika előadóterme
2024-12-19 12:00:00
Dermatology and Venereology
Dr. Sárdy Miklós
Dr. Holló Péter
Dr. Dános Kornél
Dr. Németh István Balázs
Dr. Tamási Lilla
Dr. Riesz Péter
Dr. Takácsi-Nagy Zoltán
recent years, PD-1 inhibitor ICIs have gained a significant role in the treatment of various malignant tumors, including malignant melanoma and cSCC. PD-1 inhibitors exert their effect by activating the anti-tumor immune system. They are monoclonal antibodies that block the binding of PD-L1 expressed on the surface of tumor cells to PD-1 on the surface of T cells, thereby inducing T cell-mediated antitumor immunity.
In both of our studies, we analyzed data from patients treated in everyday practice to assess real-world, clinically relevant survival outcomes. In our first study, we retrospectively analyzed the survival results of AM patients treated with a PD1 inhibitor nivolumab or pembrolizumab during a 77-month observation period. In our second study, we evaluated the data of PD1 inhibitor cemiplimab therapy inpatients with la-cSCC or m-cSCC.
We aimed to identify predictive markers based on treatment efficacy and side effect characteristics.
In our first study, the baseline characteristics of the patients studied differed from those reported in clinical trials, as several patients were of advanced age (≥ 70 years), poor performance (≥ 2 ECOG), received prior treatment, had brain metastasis (stage M1d disease) or carried BRAF V600 mutation. The majority of the examined patients would not be eligible for inclusion in phase II or III clinical trials. We observed promising and long-term outcomes in AM patients on anti-PD-1 monotherapy in a real-world setting. This analysis showed that the development of one or more irAEs was associated with superior response to anti-PD-1 ICI treatment and also proved to be an independent predictive marker for both PFS and OS.
The second study demonstrated that cemiplimab exhibited high efficacy with an acceptable safety profile, comparable to previous population-based clinical trials. It was observed that cemiplimab was effective in elderly and immunocompromised patients with multiple comorbidities.
